(Press-News.org) CHICAGO – In an analysis of a cohort that included nearly one million patients who had visited an ophthalmologist, patients who were taking oral fluoroquinolones had a higher risk of developing a retinal detachment, a serious eye condition, compared with nonusers, although the absolute risk was small, according to a study in the April 4 issue of JAMA.
"Fluoroquinolones are one of the most commonly prescribed classes of antibiotics. Their broad-spectrum antibacterial coverage and high-tissue distribution provide potency for a wide variety of community-acquired infections," according to background information in the article. Although fluoroquinolones are generally well tolerated, they have been associated with a wide array of adverse events and linked to several forms of ocular toxicity such as corneal perforations, optic neuropathy, and retinal hemorrhages. "Despite numerous case reports of ocular toxicity, a pharmacoepidemiological study of their ocular safety, particularly retinal detachment, has not been performed," the authors write. "Retinal detachment is a serious medical emergency that may lead to irreversible vision loss."
Mahyar Etminan, Pharm.D., M.Sc. (epi), of the Child and Family Research Institute of British Columbia, Vancouver, Canada, and colleagues conducted a study to examine the association between oral fluoroquinolone use and the risk of retinal detachment. The study consisted of a group of patients in British Columbia who had visited an ophthalmologist between January 2000 and December 2007. Retinal detachment cases were defined as a procedure code for retinal repair surgery within 14 days of a physician service code. Ten controls were selected for each case.
The overall cohort included 989,591 patients; within this group, 4,384 cases of retinal detachment and 43,840 corresponding controls were identified for analysis. Cases were more likely to be male and were more likely to have myopia (near-sightedness), diabetes, or have received cataract surgery. The researchers found that retinal detachment was associated with a higher likelihood of current use of fluoroquinolones (3.3 percent of cases vs. 0.6 percent of controls). For current users, the average number of days from the first fluoroquinolone prescription to the first event of a retinal detachment was 4.8 days. No risk was observed among recent users (0.3 percent of cases vs. 0.2 percent of controls) or past users (6.6 percent of cases vs. 6.1 percent of controls). The authors note that the absolute increase in the risk for this condition was small (number needed to harm = 2,500 for any use of fluoroquinolones).
No risk was observed among current users of β-lactam antibiotics or short-acting β-agonists.
"This is the first study, to our knowledge, demonstrating that oral fluoroquinolones are associated with an increase in the risk of a retinal detachment. Current users of oral fluoroquinolones were nearly 5 times more likely to be diagnosed with retinal detachment than nonusers," the researchers write, although because retinal detachment is rare among unexposed patients, the absolute risk increase is low.
The authors add that the risk of retinal detachment in their study was only elevated among current users but not among recent or past users, indicating an acute adverse event. They note that the exact mechanism of retinal detachment with fluoroquinolones is unknown.
"Future pharmacoepidemiological studies should be conducted to confirm or refute these findings," the researchers conclude.
###
(JAMA. 2012;307[13]:1414-1419. Available pre-embargo to the media at www.jamamedia.org)
Editor's Note: The study was funded by the Canadian National Institute for the Blind. The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.
To contact Mahyar Etminan, Pharm.D., M.Sc. (epi), call Aimee Taylor at 604-875-3885 or email ataylor@cfri.ca.
END
CHICAGO --The feasibility of selecting treatment based on individual molecular characteristics was demonstrated in a first-of-its kind pancreatic cancer clinical trial reported today by the Translational Genomics Research Institute (TGen) and the Virginia G. Piper Cancer Center at Scottsdale Healthcare.
The findings were announced during the American Association for Cancer Research (AACR) Annual Meeting 2012, March 31-April 4, in Chicago.
"The most important finding is that this approach is feasible and we are encouraged by preliminary evidence that this approach may ...
Johns Hopkins investigators are testing a way to use drugs that target a cholesterol pathway to enhance the cancer-killing potential of standard chemotherapy drugs. Their tests, in mouse models of pancreatic cancer, may yield new and more effective combinations of current and possibly new anti-cancer drugs.
Besides their deadly consequences, pancreatic cancer and heart disease share a connection with genetic pathways that control cholesterol and a cell signaling system known as the Hedgehog pathway. (The name refers to the shape of its mutated protein in fruit flies, ...
In a research article published April 3 in the online, open-access journal PLoS Biology, Prof. Sylvia Cremer and colleagues at the Institute of Science and Technology, Austria show how micro-infections promote social vaccination in ant societies. Like crowded megacities, ant colonies face a high risk of disease outbreaks. These are kept in check by the ants' social immune system—a set of collective hygienic behaviours and adaptive changes in interaction frequencies that acts in conjunction with the physiological, innate immune system of colony members. Prof. Cremer and ...
Top executives at Anago Cleaning Systems hosted its 2012 annual conference for their Master Franchisees in an effort to celebrate major growth and successes in 2011, and prepare for aggressive expansion and improvement throughout each territory and the nation. New and existing Master Franchisees alike attended the two-day show that was held on March 5-6, 2012 in Orlando, Florida.
The convention kicked off with opening remarks from Anago Cleaning Systems Founder, David Povlitz.
Mr. Povlitz reiterated that the vision, mission, and values of the company he founded in ...
An international team of scientists has created an innovative tool for teaching the fundamentals of epidemiology—the science of how infectious diseases move through a population.
The team teaches a workshop annually in South Africa that helps epidemiologists improve the mathematical models they use to study outbreaks of diseases like cholera, AIDS and malaria. Led by Steve Bellan from the University of California at Berkeley, the team created a new game as a teaching aid for the workshop. The exercise, which has proven extremely effective in demonstrating concepts in ...
Genetic mutations in cancer cells can lead to resistance to treatment, thereby potentially resulting in relapse. However, a new article, published April 3 in the magazine section of the online, open-access journal PLoS Biology, suggests that the converse may also happen. Steven Frank from the University of California, Irvine, and Marsha Rosner from the University of Chicago, propose that it may often be the case that a few cells become resistant before any genetic change, and then later acquire the genes to stabilize that resistance.
Why does it matter whether resistance ...
CAL Business Solutions, a Connecticut based Microsoft Dynamics GP partner, today announced that it will host the first ever New England SalesPad user group workshop. Companies using Microsoft Dynamics GP with SalesPad, an add on product for the distribution industry, will have the opportunity to come together to see new features, share ideas, network with their peers and provide input on future product developments.
The user group will be held at the Crowne Plaza hotel in Cromwell, Connecticut from 8:00-11:30am on Monday May 7th. Topics on the agenda include advanced ...
New evidence points to a hormone that leaves muscles gobbling up sugar as if they can't get enough. That factor, which can be coaxed out of fat stem cells, could lead to a new treatment to lower blood sugar and improve metabolism, according to a report in the April issue of Cell Metabolism, a Cell Press publication.
This new fat-derived hormone would appear to be a useful alternative or add-on to insulin; it can do essentially the same job, sending glucose out of the bloodstream and into muscle.
"It's like you've opened the door and now the glucose can come in," said ...
Philadelphia, PA, April 3, 2012 – A new report published online today in the Journal of the Academy of Nutrition and Dietetics systematically reviews and updates the evidence underlying the recommendation in the Dietary Guidelines for Americans 2010 to consume a diet low in energy density (ED). The report addresses the growing body of evidence linking ED, or the number of calories in a given amount of food, and body weight in adults as well as children and adolescents. The systematic review concluded that there is strong and consistent evidence in adults showing that consuming ...
The drug known as rapamycin is widely used by cancer and transplant patients, and there are hints that it might even help us put off old age and live longer. But, it also comes with a downside: rapamycin leads to diabetes in as many as 15 percent of the people who take it.
Now, researchers reporting in the April Cell Metabolism, a Cell Press publication, have figured out why that is. The drug turns the insulin signal off in muscle, to prevent muscle cells from taking blood sugar in.
"This is a drug that is pretty well known for its benefits," said Pere Puigserver ...
